Clinical trials: Proteinosis

Hereditary Pulmonary Alveolar Proteinosis

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)

• Completed
• Age: 8 years and older
• Phase 2
• Results posted

The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to partial dysfunction of the GM-CSF receptor.

Trial name

FAMPAP (NCT01511068)

Testing

Leukine

Where

2 sites in United States

Volunteers

2 people

Sponsor

Children's Hospital Medical Center, Cincinnati